Immunotherapy has demonstrated impressive clinical benefit in oncology. However, as it has established itself as a well-recognized treatment modality, further questions are emerging about how we can replicate the success observed with hematologic malignancies and melanoma, for other cancer types.
• Key limitations of current cancer immunotherapies
• Tips for developing and using novel and effective immunotherapies
• Real-world applications of immunotherapy in cancer clinics
Dana-Farber Cancer Institute (MA, USA)
Ricciuti is clinical researcher at the Dana-Farber Cancer Institute. Following the completion of his MD degree at Perugia University (Italy), Ricciuti completed his internal medicine residency at the Department of Internal Medicine of Santa Maria della Misericordia Hospital in Perugia and then enrolled in the Oncology fellowship program within the Department of Medical Oncology. Ricciuti joined the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute (DFCI) in June 2018. His research focuses on understanding mechanisms of response and resistance to immunotherapy in non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC).
Professor of Medicine
Ohio State University Wexner Medical Center and the James Comprehensive Cancer Center (both OH, USA)
Pravin Kaumaya is Professor of Medicine in Department of obstetrics and gynecology at the Ohio State University Wexner Medical Center and the James Comprehensive Cancer Center. Dr Kaumaya is internationally recognized as an expert in the fields of vaccine research with emphasis on peptide vaccines for cancer, viral diseases as well as peptide therapy for autoimmune diseases. He conducts research in the areas of tumor immunology, mechanisms of tumor cell-immune cell interactions, and immune mechanisms. The laboratory functions as an integrated translational research program with the goal of designing and developing new immunotherapies and immunologic strategies for cancer treatment and prevention. He is an inventor on several issued and pending patents for Peptide Vaccines and Therapeutic Technologies and has PD-1 and PD-L1 vaccine patents filed. He has lectured worldwide and has published over 130 peer-reviewed articles in major scientific journals. Kaumaya is an elected fellow of the American Association for the Advancement of Science (AAAS), and he was elected as the treasurer of the American Peptide Society since 2009. Kaumaya has conducted a first man/woman NCI funded and US FDA approved Phase I Trial in Cancer Patients (Stage IV) with solid tumors in several indications (breast, ovarian, gastrointestinal) at the Ohio State University James Cancer Hospital has recently been completed successfully.
Memorial Sloan-Kettering Cancer Center (NY, USA)
Slovin is Attending Physician and Member in the Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and Professor of Medicine, Department of Medicine at Joan and Sanford I. Weill Medical College of Cornell University (NY, USA). Slovin earned an MD from Jefferson Medical College (PN, USA) in Philadelphia, and a PhD from Columbia University Graduate School of Arts and Sciences in New York. She completed residency at the Mount Sinai Medical Center and fellowship Memorial Sloan Kettering Cancer Center. She is board certified in internal medicine and medical oncology.
Chief Supervisor of Predictive Molecular Patholgy lab
Department of Public Health University of Naples Federico II (Italy)
Umberto Malapelle is the Chief Supervisor of Predictive Molecular Pathology Laboratory, of the University of Naples Federico II. He was appointed in December 2015 Assistant Professor in Anatomic Pathology in School of Medicine, University of Naples Federico II. Currently his main research interest is in the field of genomic biomarkers validation and testing for predictive information in the field of lung cancer, metastatic colorectal cancer, melanoma and gastrointestinal stromal tumors. Moreover, he has developed skills in tailoring next-generation assays for a number of different applications with a special focus on the simultaneously detection of clinical relevant alterations (i.e., EGFR mutations, ALK translocation, PDL – 1 expression) in the routine setting including handling of different sample types, such as tissues and/or liquid biopsy specimens.
Updated 21 November, 2019